Frankfurt
03.02.26 | 08:14
0,114 Euro
+5,58 % +0,006
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10:00 | NextCell Pharma AB: Seven-year follow-up data from ProTrans-Repeat demonstrate sustained disease-modifying effects of ProTrans in type 1 diabetes | 44 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces long-term follow-up data from the ProTrans-Repeat study showing sustained preservation of endogenous insulin production in patients with... ► Artikel lesen | |
| 21.01. | NextCell Pharma AB: NextCell provides strategic update on focused market progression, highlighting Hong Kong as gateway to the Chinese market | 88 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") provides a strategic update on its focused market progression strategy, aimed at accelerating value creation by advancing ProTrans in adult patients... ► Artikel lesen | |
| 21.01. | NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEXTCELL PHARMA AB (PUBL) | 1 | Cision News | ||
| NEXTCELL PHARMA Aktie jetzt für 0€ handeln | |||||
| 15.01. | NextCell Pharma AB: Six-year data demonstrate a durable disease-modifying effect of ProTrans in type 1 diabetes | 106 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that six-year follow-up data indicate that a single infusion of ProTrans provides a long-lasting and clinically relevant preservation... ► Artikel lesen | |
| 02.12.25 | NextCell Pharma AB: NextCell initiates collaboration with OptiCell - strengthening its cell-handling operations | 114 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") has entered into a collaboration agreement with OptiCell Solutions AB ("OptiCell") regarding the handling, freezing, storage, and transport of cell products... ► Artikel lesen | |
| 20.11.25 | NextCell Pharma AB: NextCell Pharma appoints Eric Gustafsson as new CFO | 386 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") today announces the appointment of Eric Gustafsson as Chief Financial Officer (CFO). With extensive experience in leading financial transformations and... ► Artikel lesen | |
| 19.11.25 | NEXTCELL PHARMA AB: NextCell Pharma company presentations | 3 | Cision News | ||
| 30.10.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 4 2024/2025 | 131 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 4 for the period June 1, 2025 - August 31, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 18.09.25 | NextCell Pharma AB: NextCell Pharma AB announces CFO transition | 137 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company's CFO, Patrik Fagerholm, has decided to step down to take on a new assignment. Patrik will remain in his role throughout... ► Artikel lesen | |
| 24.07.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 3 2024/2025 | 235 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 3 for the period March 1, 2025 - May 31, 2025. This English version of the Interim Report is a translation of the Swedish version.... ► Artikel lesen | |
| 13.06.25 | NextCell Pharma AB: All Patients Successfully Treated in ProTrans-Young Study | 442 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or the "Company") announces today that all patients in the ongoing ProTrans-Young clinical trial have now successfully been treated. This milestone marks the completion... ► Artikel lesen | |
| 26.05.25 | NextCell Pharma AB: NextCell Receives US Patent for MSC Prediction Algorithm | 439 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") is pleased to announce the issuance of a US patent titled "MSC Prediction Algorithm" by the United States Patent and Trademark Office (USPTO). The patent... ► Artikel lesen | |
| 20.05.25 | NextCell Pharma AB: NextCell announces strategic collaboration with Fujifilm Irvine Scientific | 801 | GlobeNewswire (Europe) | NextCell Pharma AB's ("NextCell" or "the Company") has entered into a strategic collaboration with Fujifilm Irvine Scientific Inc. to bring together their core competences in mesenchymal stromal cells... ► Artikel lesen | |
| 25.04.25 | NextCell Pharma AB: NextCell Pharma publishes its Interim Report 2 2024/2025 | 184 | GlobeNewswire (Europe) | NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2024 - February 28, 2025. The report is available on the company's website: https://www.nextcellpharma.com/en/investorsfinancial-report.... ► Artikel lesen | |
| 15.04.25 | NextCell Pharma AB: NextCell CEO Mathias Svahn explains the latest results from ProTrans-YOUNG and his vision for the way forward | 208 | GlobeNewswire (Europe) | NextCell Pharma ("the company" or "NextCell") has published an interview where the analyst Filip Einarsson from Redeye, who currently covering NextCell, discusses with Mathias questions regarding the... ► Artikel lesen | |
| 13.03.25 | NextCell Pharma AB: Results from the Older Age Cohort in the ProTrans-Young Paediatric Study Expected in Aprilv | 444 | GlobeNewswire (Europe) | NextCell Pharma AB ("NextCell" or "the Company") announces that the last patient in the older age cohort (12-21 years) of the clinical Phase II study, ProTrans-Young, has now completed their 12-month... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,528 | +10,64 % | Evotec Aktie: Comebacktitel für 2026? | Aktionäre von Evotec müssen viel Geduld aufbringen. Seit Monaten scheitern immer wieder die Versuche der Biotech-Aktie, stabil über die 200-Tage-Linie zu springen. An oder knapp oberhalb des viel beachteten... ► Artikel lesen | |
| QIAGEN | 44,120 | +0,14 % | Qiagen beruft Mark Stevenson in den Aufsichtsrat | DJ Qiagen beruft Mark Stevenson in den Aufsichtsrat
DOW JONES--Qiagen hat Mark Stevenson als Nachfolger von Ross Levine mit Wirkung zum vergangenen Freitag in den Aufsichtsrat berufen. Stevenson... ► Artikel lesen | |
| BIONTECH | 91,55 | -0,92 % | BioNTech ernennt Kylie Jimenez zur Chief People Officer | Der Aufsichtsrat der BioNTech SE hat Kylie Jimenez mit Wirkung zum 1. März 2026 zur neuen Chief People Officer (Chief People Officer) ernannt. Die neu geschaffene Vorstandsposition umfasst die Verantwortung... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 73,01 | +0,36 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| TANGO THERAPEUTICS | 12,680 | +6,38 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,200 | +0,60 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 88,17 | -1,86 % | Structure Therapeutics gains on report suggesting it may be a top takeover target | ||
| KINIKSA PHARMACEUTICALS | 44,370 | -0,67 % | Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout | ||
| KYMERA THERAPEUTICS | 77,15 | +2,02 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader | Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,560 | +3,56 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 10,780 | +1,60 % | Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models | ||
| ARRIVENT BIOPHARMA | 23,130 | +1,80 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| MAZE THERAPEUTICS | 46,770 | +0,49 % | Maze Therapeutics stock price target reiterated at $60 by H.C. Wainwright | ||
| TARSUS PHARMACEUTICALS | 66,14 | +0,31 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| VERA THERAPEUTICS | 44,680 | -1,37 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen |
Das Unternehmen NEXTCELL PHARMA AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,114 Euro und damit +5,58 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEXTCELL PHARMA AB finden Sie auf Wallstreet Online.